These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 28224300)

  • 21. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia.
    Saglio G; Kim DW; Issaragrisil S; le Coutre P; Etienne G; Lobo C; Pasquini R; Clark RE; Hochhaus A; Hughes TP; Gallagher N; Hoenekopp A; Dong M; Haque A; Larson RA; Kantarjian HM;
    N Engl J Med; 2010 Jun; 362(24):2251-9. PubMed ID: 20525993
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha.
    Merx K; Müller MC; Kreil S; Lahaye T; Paschka P; Schoch C; Weisser A; Kuhn C; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
    Leukemia; 2002 Sep; 16(9):1579-83. PubMed ID: 12200666
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A rare BCR-ABL1 transcript in Philadelphia-positive acute myeloid leukemia: case report and literature review.
    Piedimonte M; Ottone T; Alfonso V; Ferrari A; Conte E; Divona M; Bianchi MP; Ricciardi MR; Mirabilii S; Licchetta R; Campagna A; Cicconi L; Galassi G; Pelliccia S; Leporace A; Lo Coco F; Tafuri A
    BMC Cancer; 2019 Jan; 19(1):50. PubMed ID: 30630459
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Philadelphia-negative chronic myeloid leukemia with a BCR/ABL fusion gene on chromosome 9.
    Reddy KS; Grove B
    Cancer Genet Cytogenet; 1998 Nov; 107(1):48-50. PubMed ID: 9809034
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Molecular cytogenetic characterization of Philadelphia-negative rearrangements in chronic myeloid leukemia patients.
    Bennour A; Bellâaj H; Ben Youssef Y; Elloumi M; Khelif A; Saad A; Sennana H
    J Cancer Res Clin Oncol; 2011 Sep; 137(9):1329-36. PubMed ID: 21739181
    [TBL] [Abstract][Full Text] [Related]  

  • 26. BCR-ABL1(+) acute myeloid leukemia: clonal selection of a BCR-ABL1(-) subclone as a cause of refractory disease with nilotinib treatment.
    Neuendorff NR; Schwarz M; Hemmati P; Türkmen S; Bommer C; Burmeister T; Dörken B; le Coutre P; Arnold R; Westermann J
    Acta Haematol; 2015; 133(2):237-41. PubMed ID: 25401297
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Overview of clinical and genetic features of CML patients with variant Philadelphia translocations involving chromosome 7: A case series.
    Bayrak AG; Daglar Aday A; Yavuz AS; Nalcaci M; Ozbalak MM; Cefle K; Ozturk S; Palanduz S
    Leuk Res; 2021 Dec; 111():106725. PubMed ID: 34634595
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tyrosine kinase inhibitors for the treatment of Philadelphia chromosome-positive adult acute lymphoblastic leukemia.
    Piccaluga PP; Paolini S; Martinelli G
    Cancer; 2007 Sep; 110(6):1178-86. PubMed ID: 17701954
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serial monitoring of BCR-ABL by peripheral blood real-time polymerase chain reaction predicts the marrow cytogenetic response to imatinib mesylate in chronic myeloid leukaemia.
    Wang L; Pearson K; Pillitteri L; Ferguson JE; Clark RE
    Br J Haematol; 2002 Sep; 118(3):771-7. PubMed ID: 12181044
    [TBL] [Abstract][Full Text] [Related]  

  • 30. NOVEL-1st: an observational study to assess the safety and efficacy of nilotinib in newly diagnosed patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase in Taiwan.
    Hwang WL; Chen TC; Lin HY; Chang MC; Hsiao PC; Bai LY; Kuo CY; Chen YC; Liu TC; Gau JP; Wang PN; Hwang WS; Kuo MC; Liu CY; Liu YC; Ma MC; Su NW; Wang CC; Wu YY; Yao M; Yeh SP; Cheng HW; Lee YM; Ku FC; Tang JL
    Int J Hematol; 2022 May; 115(5):704-712. PubMed ID: 35212915
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of residual CD34(+) Ph(+) progenitor cells in chronic myeloid leukemia patients who have complete cytogenetic response during first-line nilotinib therapy.
    Defina M; Ippoliti M; Gozzetti A; Abruzzese E; Castagnetti F; Crupi R; Tiribelli M; Breccia M; Salvucci M; Aprile L; Baratè C; Gozzini A; Rosti G; Lauria F; Bocchia M
    Cancer; 2012 Nov; 118(21):5265-9. PubMed ID: 22517301
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prediction for sustained deep molecular response of BCR-ABL1 levels in patients with chronic myeloid leukemia in chronic phase.
    Sasaki K; Kantarjian H; O'Brien S; Ravandi F; Konopleva M; Borthakur G; Garcia-Manero G; Wierda W; Daver N; Ferrajoli A; Takahashi K; Jain P; Rios MB; Pierce S; Jabbour E; Cortes JE
    Cancer; 2018 Mar; 124(6):1160-1168. PubMed ID: 29266206
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Detection of
    Uzoma IC; Taiwo IA; Nna EO; Durosinmi MA; Ukaejiofo EO
    Niger J Clin Pract; 2019 Jan; 22(1):51-55. PubMed ID: 30666020
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Complete cytogenetic and molecular response after imatinib treatment for chronic myeloid leukemia in a patient with atypical karyotype and BCR-ABL b2a3 transcript.
    Pienkowska-Grela B; Woroniecka R; Solarska I; Kos K; Pastwińska A; Konopka L; Majewski M
    Cancer Genet Cytogenet; 2007 Apr; 174(2):111-5. PubMed ID: 17452251
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase 3 study of nilotinib vs imatinib in Chinese patients with newly diagnosed chronic myeloid leukemia in chronic phase: ENESTchina.
    Wang J; Shen ZX; Saglio G; Jin J; Huang H; Hu Y; Du X; Li J; Meng F; Zhu H; Hu J; Wang J; Hou M; Hertle S; Menssen HD; Ortmann CE; Tribouley C; Yuan Y; Baccarani M; Huang X
    Blood; 2015 Apr; 125(18):2771-8. PubMed ID: 25766724
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Location of the BCR/ABL fusion genes on both chromosomes 9q34 in Ph negative chronic myeloid leukemia.
    Michalová K; Zemanová Z; Bkezinová J; Moravcová J; Oltová A; Sobotka J; Kuglík P; Kozak T; Sindelarová L; Jankovská M; Obomilová A; Sieglová Z; Polák J; Nádvorníková S; Haskovec C
    Leuk Lymphoma; 2002 Aug; 43(8):1695-700. PubMed ID: 12400616
    [TBL] [Abstract][Full Text] [Related]  

  • 37. BCR-ABL1 transcript at 3 months predicts long-term outcomes following second generation tyrosine kinase inhibitor therapy in the patients with chronic myeloid leukaemia in chronic phase who failed Imatinib.
    Kim DD; Lee H; Kamel-Reid S; Lipton JH
    Br J Haematol; 2013 Mar; 160(5):630-9. PubMed ID: 23278256
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Extramedullary BCR-ABL1-negative myeloid leukemia in a patient with chronic myeloid leukemia and synchronous cytogenetic abnormalities in Philadelphia-positive and -negative clones during imatinib therapy.
    Quintás-Cardama A; Kantarjian H; Abruzzo LV; Cortes J
    Leukemia; 2007 Nov; 21(11):2394-6. PubMed ID: 17690707
    [No Abstract]   [Full Text] [Related]  

  • 39. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
    Steinberg M
    Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
    [TBL] [Abstract][Full Text] [Related]  

  • 40. BCR-ABL1 e6a2 transcript in chronic myeloid leukemia: biological features and molecular monitoring by droplet digital PCR.
    Zagaria A; Anelli L; Coccaro N; Tota G; Casieri P; Cellamare A; Impera L; Brunetti C; Minervini A; Minervini CF; Delia M; Cumbo C; Orsini P; Specchia G; Albano F
    Virchows Arch; 2015 Sep; 467(3):357-63. PubMed ID: 26149409
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.